RGNX - REGENXBIO Inc.
39.83 -0.10 (-0.25%)
After hours: 4:11PM EDT
| Previous Close | 37.92 |
| Open | 37.98 |
| Bid | 35.88 x 1100 |
| Ask | 41.25 x 2200 |
| Day's Range | 37.78 - 40.64 |
| 52 Week Range | 30.38 - 81.40 |
| Volume | 594,366 |
| Avg. Volume | 574,955 |
| Market Cap | 1.47B |
| Beta (3Y Monthly) | 1.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.36 |
| Earnings Date | Nov 5, 2019 - Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 83.00 |
- Zacks
REGENXBIO (RGNX) Catches Eye: Stock Jumps 5.8%
REGENXBIO (RGNX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
- American City Business Journals
This Rockville biotech has added another deal to its growth plan
The deal gives RegenxBio an option for exclusive, worldwide commercial licensing rights to the biopharma’s SCS Microinjector, its delivery method for gene therapies.
- Zacks
Ultragenyx-GeneTx Get Orphan Drug Status for GTX-102 From FDA
The FDA grants Orphan Drug and Rare Pediatric Disease designations to Ultragenyx (RARE) and partner GeneTx Biotherapeutics' GTX-102 for the treatment of Angelman Syndrome.
- PR Newswire
REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314
- REGENXBIO expands RGX-314 gene therapy program to evaluate Clearside's proprietary, in-office SCS Microinjector™ platform targeting suprachoroidal space delivery - Recent publication in The Journal of ...
- PR Newswire
REGENXBIO to Present at Upcoming Investor Conferences
ROCKVILLE, Md. , Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based ...
- Motley Fool
3 Top Biotech Stocks to Buy Right Now
Patent cliffs and pipeline risks are among the reasons these biologic drug specialists are attractively priced today.
- PR Newswire
REGENXBIO to Present Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting in October
ROCKVILLE, Md., Aug. 27, 2019 /PRNewswire/ -- REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that an interim trial update from the RGX-314 Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration (wet AMD) will be reported during a presentation at the Retina Subspecialty Day program of the American Academy of Ophthalmology (AAO) 2019 Annual Meeting in San Francisco, CA. The results will be presented by Dr. Jeffrey S. Heier, M.D., Co-President and Director of Retina Research at Ophthalmic Consultants of Boston, and primary investigator for the trial.
- Zacks
Ultragenyx (RARE) Focuses on Pipeline Amid Low Revenues
Ultragenyx (RARE) focuses on the development of pipeline candidates. Being a new commercial company with lower revenues, development or regulatory setbacks could result in higher operating expenses.
- GuruFocus.com
Regenxbio Inc (RGNX) President and CEO Kenneth T. Mills Sold $563,250 of Shares
President and CEO of Regenxbio Inc (30-Year Financial, Insider Trades) Kenneth T. Mills (insider trades) sold 15,000 shares of RGNX on 08/19/2019 at an average price of $37.55 a share. Continue reading...
- Thomson Reuters StreetEvents
Edited Transcript of RGNX earnings conference call or presentation 7-Aug-19 8:30pm GMT
Q2 2019 Regenxbio Inc Earnings Call
Motley FoolRegenxbio Inc. (RGNX) Q2 2019 Earnings Call Transcript
RGNX earnings call for the period ending June 30, 2019.
- Zacks
Regenxbio (RGNX) Reports Q2 Loss, Misses Revenue Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of -44.00% and -65.15%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
REGENXBIO Reports Second Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD
ROCKVILLE, Md. , Aug. 7, 2019 /PRNewswire/ -- Reports further positive interim update from RGX-314 Phase I/IIa trial for Wet AMD Well-tolerated at all doses Dose-dependent protein expression levels observed ...
- Simply Wall St.
Is REGENXBIO Inc.'s (NASDAQ:RGNX) CEO Overpaid Relative To Its Peers?
Ken Mills has been the CEO of REGENXBIO Inc. (NASDAQ:RGNX) since 2009. This report will, first, examine the CEO...
- PR Newswire
REGENXBIO Announces New License Agreement with Pfizer for the Treatment of Friedreich's Ataxia Using NAV® AAV9 Vector
ROCKVILLE, Md., July 31, 2019 /PRNewswire/ -- REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, today announced it entered into a license agreement with Pfizer Inc. Under the terms of the agreement, REGENXBIO has granted Pfizer a non-exclusive worldwide license, with rights to sublicense, to REGENXBIO's NAV AAV9 vector for the development and commercialization of gene therapies for the treatment of Friedreich's ataxia, the most common hereditary ataxia.
- PR Newswire
REGENXBIO To Host Conference Call on August 7 to Discuss Second Quarter 2019 Financial Results and Recent Operational Highlights
ROCKVILLE, Md. , July 30, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based ...
- PR Newswire
REGENXBIO Expands Pipeline Using NAV Vectors to Deliver Therapeutic Antibodies for the Treatment of Hereditary Angioedema and Neurodegenerative Diseases
ROCKVILLE, Md., July 24, 2019 /PRNewswire/ -- REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced an expansion of its pipeline to include novel treatments for hereditary angioedema (HAE) and neurodegenerative diseases, including tauopathies, using NAV Vectors to deliver therapeutic antibodies.
- PR Newswire
REGENXBIO and Neurimmune Announce Collaboration to Develop Vectorized Antibodies for the Treatment of Neurodegenerative Diseases
ROCKVILLE, Md. and ZURICH, July 24, 2019 /PRNewswire/ -- REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform and Neurimmune AG, a leading clinical-stage Swiss biotech company translating human immune memory into antibody therapeutics, today announced an exclusive license, development and commercialization agreement to discover and develop novel AAV gene therapies using NAV Vectors to deliver human antibodies against targets implicated in chronic neurodegenerative diseases, including tauopathies.
- GuruFocus.com
Regenxbio Inc (RGNX) President and CEO Kenneth T. Mills Sold $742,350 of Shares
President and CEO of Regenxbio Inc (30-Year Financial, Insider Trades) Kenneth T. Mills (insider trades) sold 15,000 shares of RGNX on 07/19/2019 at an average price of $49.49 a share. Continue reading...
- Zacks
Are Options Traders Betting on a Big Move in REGENXBIO (RGNX) Stock?
Investors need to pay close attention to REGENXBIO (RGNX) stock based on the movements in the options market lately.
- Insider Monkey
Here’s What Hedge Funds Think About Regenxbio Inc (RGNX)
Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing […]
- PR Newswire
REGENXBIO to Present at the Raymond James 2019 Life Sciences and MedTech Conference
ROCKVILLE, Md. , June 11, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based ...
- Thomson Reuters StreetEvents
Edited Transcript of RGNX earnings conference call or presentation 7-May-19 8:30pm GMT
Q1 2019 Regenxbio Inc Earnings Call
- American City Business Journals
FDA approves most expensive gene therapy ever — and here is its connection to Penn
The delivery of the Novartis gene therapy for a lethal disease has a strong tie to Penn researchers.
- Zacks
REGENXBIO (RGNX) Catches Eye: Stock Jumps 7.4%
REGENXBIO (RGNX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
